Pre- and postnatal transplantation of fetal mesenchymal stem cells in osteogenesis imperfecta: A two-center experience

Stem Cells Translational Medicine

Volumn 3, Issue 2, 2014, Pages 255-264

  Götherström, Cecilia ^a   Westgren, Magnus ^a   Steven Shaw, S W ^b   Åström, Eva ^a   Biswas, Arijit ^c   Byers, Peter H ^d   Mattar, Citra N Z ^c   Graham, Gail E ^e   Taslimi, Jahan ^f   Ewald, Uwe ^g   Fisk, Nicholas M ^h   Yeoh, Allen E J ⁱ   Lin, Ju Li ^b   Cheng, Po Jen ^b   Choolani, Mahesh ^c   Le Blanc, Katarina ^a   Chan, Jerry K Y ^c,j,k  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d UNIVERSITY OF WASHINGTON   (United States)

^e CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^f UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^g UPPSALA UNIVERSITY   (Sweden)

^h UNIVERSITY OF QUEENSLAND   (Australia)

ⁱ NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^j Women's and Children's Hospital   (Singapore)

^k DUKE NUS MEDICAL SCHOOL   (Singapore)

more..

Author keywords

Cell therapy; In utero transplantation; Mesenchymal stem cells; Mesenchymal stromal cells; Osteogenesis imperfecta; Prenatal transplantation

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; COLECALCIFEROL; ZOLEDRONIC ACID;

ALLOIMMUNITY; ARTICLE; CASE REPORT; CHILD; ENGRAFTMENT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FETUS; FLUORESCENCE IN SITU HYBRIDIZATION; FRACTURE; GENOTYPING TECHNIQUE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFANT; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; NEWBORN; OSTEOGENESIS IMPERFECTA; PERINATAL PERIOD; PRENATAL PERIOD; PRESCHOOL CHILD; REAL TIME POLYMERASE CHAIN REACTION; RETRANSPLANTATION;

CELL THERAPY; IN UTERO TRANSPLANTATION; MESENCHYMAL STEM CELLS; MESENCHYMAL STROMAL CELLS; OSTEOGENESIS IMPERFECTA; PRENATAL TRANSPLANTATION;

BONE DEVELOPMENT; EMBRYONIC STEM CELLS; FEMALE; FETAL DISEASES; FETUS; GENOTYPE; HUMANS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; OSTEOGENESIS IMPERFECTA; PEDIGREE; PREGNANCY;

EID: 84894097560     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2013-0090     Document Type: Article

References (45)

1. Forlino A, Cabral WA, Barnes AM et al. New perspectives on osteogenesis imperfecta. Nat Rev Endocrinol 2011;7:540-557.
2. Steiner RD, Pepin MG, Byers PH. Osteogenesis Imperfecta. In: Pagon RA, Bird TD, Dolan CR et al., eds. GeneReviews. Seattle, WA: University of Washington, Seattle, 1993.
3. Glorieux FH, Bishop NJ, Plotkin H et al. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998;339:947-952.
4. Bishop N. Characterising and treating osteogenesis imperfecta. Early Hum Dev 2010; 86:743-746.
5. Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-147.
6. Le Blanc K, Pittenger M. Mesenchymal stem cells: Progress toward promise. Cytotherapy 2005;7:36-45.
7. Le Blanc K, Ringdén O. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005;11: 321-334.
8. Horwitz EM, Gordon PL, Koo WK et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci USA 2002;99:8932-8937.
9. Bernardo ME, Zaffaroni N, Novara F et al. Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res 2007;67:9142-9149.
10. Prockop DJ. Defining the probability that a cell therapy will produce a malignancy. Mol Ther 2010;18:1249-1250.
11. Prockop DJ, Brenner M, Fibbe WE et al. Defining the risks of mesenchymal stromal cell therapy. Cytotherapy 2010;12:576-578.
12. von Bahr L, Batsis I, Moll G et al. Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation. STEM CELLS 2012;30:1575-1578.
13. Salem HK, Thiemermann C. Mesenchymal stromal cells: Current understanding and clinical status. STEM CELLS 2010;28:585-596.
14. Zhang ZY, Teoh SH, Hui JH et al. The potential of human fetal mesenchymal stem cells for off-the-shelf bone tissue engineering application. Biomaterials 2012;33:2656-2672.
15. Pereira RF, O'Hara MD, Laptev AV et al. Marrow stromal cells as a source of progenitor cells for nonhematopoietic tissues in transgenic mice with a phenotype of osteogenesis imperfecta. Proc Natl Acad Sci USA 1998;95: 1142-1147.
16. Prockop DJ. Repair of tissues by adult stem/progenitor cells (MSCs): Controversies, myths, and changing paradigms. Mol Ther 2009;17:939-946.
17. Prockop DJ, Kota DJ, Bazhanov N et al. Evolving paradigms for repair of tissues by adult stem/progenitor cells (MSCs). J Cell Mol Med 2010;14:2190-2199.
18. Otsuru S, Gordon PL, Shimono K et al. Transplanted bone marrow mononuclear cells and MSCs impart clinical benefit to children with osteogenesis imperfecta through different mechanisms. Blood 2012;120:1933-1941.
19. Götherström C. Immunomodulation by multipotent mesenchymal stromal cells. Transplantation 2007;84(suppl):S35-S37.
20. Götherström C, Ringdén O, Tammik C et al. Immunologic properties of human fetal mesenchymal stem cells. Am J Obstet Gynecol 2004;190:239-245.
21. Götherström C, Ringdén O, Westgren M et al. Immunomodulatory effects of human foetal liver-derived mesenchymal stem cells. Bone Marrow Transplant 2003;32:265-272.
22. Zhang ZY, Teoh SH, Chong MS. et al. Superior osteogenic capacity for bone tissue engineering of fetal compared with perinatal and adult mesenchymal stem cells. STEM CELLS 2009;27:126-137.
23. Chan J, Waddington SN, O'Donoghue K et al. Widespread distribution and muscle differentiation of human fetal mesenchymal stem cells after intrauterine transplantation in dystrophic mdx mouse. STEM CELLS 2007;25: 875-884.
24. Kennea NL, Waddington SN, Chan J et al. Differentiation of human fetal mesenchymal stem cells into cells with an oligodendrocyte phenotype. Cell Cycle 2009;8:1069-1079.
25. Götherström C, West A, Liden J et al. Difference in gene expression between human fetal liver and adult bone marrow mesenchymal stem cells. Haematologica 2005;90:1017-1026.
26. Guillot PV, Gotherstrom C, Chan J et al. Human first-trimester fetal MSC express pluripotency markers and grow faster and have longer telomeres than adult MSC. STEM CELLS 2007; 25:646-654.
27. Choolani M, Chan J, Fisk NM. Fetal therapy: 2020 and beyond. Prenat Diagn 2010;30: 699-701.
28. Tiblad E, Westgren M. Fetal stem-cell transplantation. Best Pract Res Clin Obstet Gynaecol 2008;22:189-201.
29. Roybal JL, Santore MT, Flake AW. Stem cell and genetic therapies for the fetus. Semin Fetal Neonatal Med 2010;15:46-51.
30. Mattar CN, Biswas A, Choolani M et al. The case for intrauterine stem cell transplantation. Best Pract Res Clin Obstet Gynaecol 2012; 26:683-695.
31. Guillot PV, Abass O, Bassett JH et al. Intrauterine transplantation of human fetalmesenchymal stem cells from first-trimester blood repairs bone andreduces fractures inosteogenesis imperfecta mice. Blood 2008;111:1717-1725.
32. Vanleene M, Saldanha Z, Cloyd KL et al. Transplantation of human fetal blood stem cells in the osteogenesis imperfecta mouse leads to improvement in multiscale tissue properties. Blood 2011;117:1053-1060.
33. Panaroni C, Gioia R, Lupi A et al. In utero transplantation of adult bone marrow de creasesperinatal lethality and rescues the bone phenotype in the knockin murine model for classical, dominant osteogenesis imperfecta. Blood 2009;114:459-468.
34. Le Blanc K, Götherström C, Ringdén O et al. Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta. Transplantation 2005;79:1607-1614.
35. Sundin M, Ringdén O, Sundberg B et al. No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients. Haematologica 2007;92:1208-1215.
36. Svensson EM, Anderung C, Baubliene J et al. Tracing genetic change over time using nuclear SNPs in ancient and modern cattle. Anim Genet 2007;38:378-383.
37. Miller CA III, Martinat MA, Hyman LE. Assessment of aryl hydrocarbon receptor complex interactions using pBEVY plasmids: Expression vectors with bi-directional promoters for use in Saccharomyces cerevisiae. Nucleic Acids Res 1998;26:3577-3583.
38. Alizadeh M, Bernard M, Danic B et al. Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction. Blood 2002;99:4618-4625.
39. Horwitz EM, Prockop DJ, Fitzpatrick LA et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 1999;5:309-313.
40. Horwitz EM, Prockop DJ, Gordon PL et al. Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood 2001;97:1227-1231.
41. Niyibizi C, Wang S, Mi Z et al. The fate of mesenchymal stem cells transplanted into immunocompetent neonatal mice: Implications for skeletal gene therapy via stem cells. Mol Ther 2004;9:955-963.
42. Lee RH, Pulin AA, Seo MJ et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 2009;5:54-63.
43. Jones GN, Moschidou D, Lay K et al. Upregulating CXCR4 in human fetal mesenchymal stem cells enhances engraftment and bone mechanics in a mouse model of osteogenesis imperfecta. STEM CELLS TRANSLATIONAL MEDICINE 2012;1:70-78.
44. Rao SH, Evans KD, Oberbauer AM et al. Bisphosphonate treatment in the oim mouse model alters bone modeling during growth. J Biomech 2008;41:3371-3376.
45. Pataki A, Müller K, Green JR et al. Effects of short-term treatment with the bisphosphonates zoledronate and pamidronate on rat bone: A comparative histomorphometric study on the cancellous bone formed before, during, and after treatment. Anat Rec 1997;249:458-468.